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Pharmacologic agents capable of increasing kinase function would be useful for treating diseases
associated with reduced kinase activity, such as inherited forms of Parkinson’s disease. In this
issue, Hertz et al. report an innovative approach for activating the Parkinson’s-associated kinase
PINK1 in cells with an ATP-derived neo-substrate.Small molecules that modulate the activ-
ity of protein targets are powerful tools
for probing biology and can serve as
starting points for developing life-saving
therapeutics. In particular, compounds
that inhibit protein kinase activity have
attracted considerable attention because
they have the potential to treat conditions
characterized by rampant kinase activa-
tion, such as cancer and inflammatory
disease (Figure 1A). Small-molecule in-
hibitors now exist for many human ki-
nases, and as of this writing, there are
14 FDA-approved kinase inhibitor drugs.
In contrast, there are very few examples
of small molecules that can activate
kinases, even though such compounds
could prove useful as drugs to treat dis-
eases linked to impaired kinase function,
such as neurodegenerative diseases and
diabetes. In this issue of Cell, Hertz et al.
(2013) describe an exciting approach for
pharmacologically activating kinase func-
tion—namely, providing a kinase with
a ‘‘bumped’’ ATP substrate (neo-sub-
strate) that is processed with higher cata-
lytic efficiency than its native substrate
(Figure 1B).
Why are there so few small-molecule
kinase activators? This is likely because
the molecular constraints required for
kinase activation are arguably more strin-
gent than those imposed upon inhibition.
A small-molecule activator needs to exert
its effect while preserving the multiple
essential steps of catalysis, such as sub-
strate binding, transition-state stabiliza-
tion, and product release. An inhibitor
need only interfere with one of these pro-
cesses to shut down the catalytic cycle.
Most of the known examples of small-716 Cell 154, August 15, 2013 ª2013 Elseviemolecule kinase activators rely on binding
to an allosteric site in order to shift the
conformational equilibrium and favor the
active over inactive kinase conformation
(Simpson et al., 2009). Although allosteric
regulation can be effective, it is only
feasible for kinases that possess a well-
characterized allosteric site.
Hertz et al. (2013) apply their strategy
in a therapeutically relevant context to
increase the catalytic activity of PTEN-
induced kinase 1 (PINK1), a mitochondrial
kinase in which loss-of-function muta-
tions have been linked to the develop-
ment of early-onset familial Parkinson’s
disease (PD) (Schapira, 2008). PD, char-
acterized by loss of the dopaminergic
neurons in the substantia nigra, is the sec-
ond most common neurodegenerative
disease, affecting about 1% of those
over 60 years of age in industrialized
countries and affecting up to 4% of those
older than 80 years (de Lau and Breteler,
2006). PD is primarily an idiopathic dis-
ease, and the standard treatment remains
L-DOPA (the biosynthetic precursor to
dopamine), which treats the symptoms
rather than the causes of the disease.
Mitochondrial dysfunction has long
been associated with parkinsonism,
and the identification of mutations in
mitochondrial proteins has pointed to a
possible genetic link to the disease.
Defects in two mitochondrial proteins—
PINK1, a Ser/Thr kinase, and PRK2
(Parkin), an E3 ubiquitin ligase—have
been linked to familial PD. PINK1 and Par-
kin are essential players in the elimination
of damaged mitochondria, a process
known as mitophagy. Upon induction of
mitochondrial damage, Parkin is rapidlyr Inc.recruited from the cytosol to damaged
(but not to healthy) mitochondria, where
it ubiquitinates its substrates, thereby
stimulating mitochondrial degradation
(Narendra et al., 2010). Selective recruit-
ment of Parkin requires PINK1, which
promotes Parkin binding through phos-
phorylation of Mfn2, a recently identified
mitochondrial Parkin receptor (Chen and
Dorn, 2013). Consistent with a neuro-
protective role of PINK1 kinase activity,
the most deleterious clinically relevant
mutations in PINK1 occur in the kinase
domain and inhibit catalysis (Song et al.,
2013), suggesting that activation of
PINK1mutants with reduced kinase activ-
ity may constitute an effective therapeutic
approach in certain forms of PD.
Hertz et al. (2013) investigate strategies
to increase PINK1 kinase activity with
pharmacologic agents. Although there
is no available structural information on
PINK1 (which precludes the rational
designof anallosteric activator), sequence
analysis of the kinase domain enables the
authors to identify regions of divergence
from the canonical kinase fold, suggesting
that PINK1 could have altered nucleotide
binding specificity. In addition, their own
widely recognized studies have shown
that kinases with a single mutation at the
‘‘gatekeeper’’ residue can accept N6-
modified ATP analogs (the ‘‘bump-and-
hole’’ strategy for engineering analog-sen-
sitive kinase alleles). Motivated by these
findings, the authors identify the ATP
analog N6-furfuryl ATP (kinetin triphos-
phate, KTP) (Figure 1B) as a substrate
that PINK1 accepts with higher catalytic
efficiency (increased Vmax and lower Km)
than its native substrate, ATP. This would
Figure 1. Approaches to Modulate Cellular ATPase Activity in a Therapeutically Relevant
Manner
(A) Efforts to block receptor tyrosine kinase activation have led to the development of small-molecule
inhibitors of the EGFR tyrosine kinase, which are FDA approved for the treatment of cancer.
(B) In this issue, Shokat and colleagues (Hertz et al., 2013) describe an approach for increasing PINK1
kinase activity with an ATP-derived neo-substrate, KTP, which can be generated intracellularly by feeding
cells kinetin. Impairment of PINK1 kinase activity leads to defects in the mitochondrial elimination pathway
and has been linked to early-onset familial PD.
(C) The neo-substrate strategy for ATPase activation presents a unique opportunity to increase the activity
of other ATPases whose loss of function has been linked to human disease, such asmembers of the AAA+
family.be a nice biochemical finding on its own,
but its greater utility would be limited
because KTP, like other nucleoside tri-
phosphates, is not expected to be cell
permeable or stable.
Remarkably, the authors find that
KTP can be generated intracellularly by
feeding cells kinetin (N6-furfuryl adenine),
which is enzymatically ribosylated and
phosphorylated to give the nucleoside
triphosphate (Figure 1B). When combined
with oxidative stress (in the form of chem-
ically induced mitochondrial depolariza-
tion), kinetin treatment of HeLa cells
transfected with the catalytically deficient
PINK1 G309D mutant or neuronal cells
containing wild-type PINK1 results inrescued mitochondrial Parkin recruit-
ment, reduced mitochondrial motility,
and antiapoptotic effects that are consis-
tent with increased PINK1 activity,
thereby validating this neo-substrate
strategy for PINK1 activation.
Although familial PD associated with
inactivating mutations in PINK1 is rare,
treatment options for PD are limited, and
this study shows that pharmacologic
PINK1 activation with kinetin may consti-
tute a viable therapeutic route in certain
instances of the disease. Unfortunately,
Parkin lies downstream of PINK1 in
the mitophagic pathway and is more
frequently mutated in PD (Schapira,
2008); it is unlikely that PINK1 activationCell 15will be therapeutically effective in treating
PD caused by Parkin dysfunction.
Importantly, this study brings to light
the unrealized therapeutic potential of
drugging kinases with neo-substrate
small-molecule activators rather than
inhibitors. Adenine-like molecules, such
as the pyrazolopyrimidine-based com-
pounds, can act as potent and specific
kinase inhibitors. It is possible that the
vast available knowledge for such specific
kinase binders will aid in the identifica-
tion of other adenine-related compounds
that can be intracellularly converted
into nucleoside triphosphates and used
as specific neo-substrate activators for
kinases in general.
Moreover, ATPases constitute one of
the larger superfamilies in the human
proteome, but we lack cell-permeable
small-molecule activators for almost all
of these proteins. Because ATP hydroly-
sis is a common feature shared by these
enzymes, the neo-substrate strategy
outlined by Hertz et al. (2013) could
present a broadly applicable approach
to activating ATPase function. In partic-
ular, the AAA+ (ATPases associated
with diverse cellular activities) family rep-
resents a large class of ATP-hydrolyzing
proteins whose loss of function has
been implicated in human diseases
such as neuronal dysfunctions, bone
disease, and ciliopathy (White and Laur-
ing, 2007) (Figure 1C). Although small-
molecule modulation of AAA+ proteins
is largely unexplored, ATP-competitive
inhibitors for dynein and p97/VCP have
been reported recently (Chou et al.,
2011; Firestone et al., 2012). Character-
izing these compounds will shed light
on the molecular recognition parameters
for binding the AAA+ ATP pocket and
may aid in the design of neo-substrate
activators for this protein family.
There will be several steps before
kinetin or related compounds can be
developed as therapeutic agents. The
findings reported by Hertz et al. (2013)
represent an exciting first step and estab-
lish a new paradigm for using chemicals
to control enzyme function in cellular
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Based on a massive transcription factor location analysis within a single cell type, in this issue
Yan et al. find that the greatmajority of occupancies occur within dense clusters of up to 100 factors
that almost invariably contain cohesins. Retention of cohesins at cluster sites during mitosis raises
the possibility that they contribute to transcriptional memory during the cell cycle.Transcriptional regulators function com-
binatorially to control eukaryotic gene
expression at the right place, time, and
level. Transcription-factor-binding sites
cluster at regulatory elements that can
be promoter proximal but also be located
up to hundreds of kilobases away. Juxta-
position of cis elements might confer
synergy in binding to chromatin and in
the recruitment of coregulatory mole-
cules. Most known enhancer elements
bind tissue- and gene-specific factors
in combination with widely expressed
DNA-binding proteins.
In this issue of Cell, Yan et al. (2013)
take the analysis of transcription factor
occupancy at enhancers to a new level
by analyzing in a single cell type over
100 transcription factors by ChIP-seq
(chromatin immunoprecipitation followed
by second-generation sequencing),
including DNA-binding and nonbinding
coregulators. The number of factors
examined exceeds the total number of
transcription factors published previouslyby the ENCODE project (Gerstein et al.,
2012).
Transcription-factor-binding sites vary
in number from 300 to 45,000 but,
notably, occur in clusters of up to 100
transcription factors confined on average
to less than 2 kb in size. Cluster sizes
correlate with gene expression and
enhancer chromatin marks as one might
expect but, surprisingly, clusters include
factors that share few functional GO
annotations. Although clusters of tran-
scription factor binding have been
observed in multiple recent studies (so-
called high occupancy or HOT regions;
MacArthur et al., 2009; Yip et al., 2012),
the sheer number of transcription factors
examined in the present study reveals a
far greater degree of transcription factor
clustering than previously observed.
Yan et al. point out that a substantial
number of factors must be examined to
observe the clusters, and one would
expect that further mapping of additional
factors will show how commonly clusterscapture the majority of binding. The
authors also find that the vast majority of
clusters containing at least 20 transcrip-
tion factors are marked by the presence
of cohesin. Previous experiments in
Drosophila and mice also found that
nearly all cis-regulatory modules are
bound by cohesin and/or its loading
factors (Kagey et al., 2010; Schaaf et al.,
2013), but recent studies of co-occu-
pancy of large numbers of factors in
human cells do not find cohesin as part
of almost all clusters (Gerstein et al.,
2012; Yip et al., 2012). Again, furthermap-
ping of the locations of larger numbers
of factors in diverse species and cell
types should resolve this apparent
discrepancy. Importantly, each study
defined clusters in a distinct way and
employed different methods of analysis.
Future work should reveal which con-
clusions are robust to the different meth-
odological approaches.
Cohesins in combination with mediator
and/or CTCF are thought to aid in forming
